Quantcast
Last updated on April 24, 2014 at 5:22 EDT

Latest Symphogen A/S Stories

2014-02-25 23:36:32

Gallus BioPharmaceuticals, LLC, a premier pure-play biologics contract manufacturing organization has signed a manufacturing agreement with Symphogen, A/S, a private biopharmaceutical company developing recombinant monoclonal antibody mixtures for the treatment of cancer. St. Louis, Missouri (PRWEB) February 25, 2014 Gallus BioPharmaceuticals, LLC (Gallus), a premier pure-play biologics contract manufacturing organization (CMO) has signed a manufacturing agreement with Symphogen, A/S...

2014-01-14 16:25:04

COPENHAGEN, Denmark, January 14, 2014 /PRNewswire/ -- Symphogen A/S, a private biopharmaceutical company with leadership in recombinant antibody mixtures for therapeutic use, today presented its achievements in 2013 and outlook for 2014 at JP Morgan's 32nd Annual Healthcare Conference in San Francisco, California. The presentation was made by Kirsten Drejer, CEO. Pipeline update Symphogen has continued to expand its oncology pipeline to include projects that...

2013-12-20 04:20:34

COPENHAGEN, Denmark, December 20, 2013 /PRNewswire/ -- Symphogen A/S, a private biopharmaceutical company with leadership in recombinant antibody mixtures for therapeutic use, today announces the appointment of Annika Espander Jansson as a Non-Executive Director of the Board, with effect from 19 December 2013. Annika has over twenty years' experience in the healthcare sector, both as a sell-side analyst and investor. She has a proven track record in strategic...

2013-05-02 08:37:30

COPENHAGEN, Denmark, May 2, 2013 /PRNewswire/ -- Symphogen will host a conference call today (2 May 2013) to discuss the announcement at 13:00 CET / 12:00 BST; details on how access this call and the accompanying presentation are below Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that it closed an expansion of its previously announced EUR100 million financing attaining a total of a EUR141 million placement of preferred stock to a...

2012-09-05 22:22:16

COPENHAGEN, Denmark, September 6, 2012 /PRNewswire/ -- - Symphogen Will Host a Conference Call Today (Thursday 6 September 2012) to Discuss the Announcement at 11:30 CET/ 10:30 BST, Details on How Access This Call and the Accompanying Presentation are Below. - A novel investigational antibody mixture targeting the epidermal growth factor receptor (EGFR) Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, a class of antibody...

2008-07-16 09:01:20

COPENHAGEN, Denmark and STOCKHOLM, Sweden- July 16, 2008. Symphogen A/S and Biovitrum AB (publ) (STO: BVT) today announced the recruitment of the first patient into a Phase II clinical trial, initiated in June, to evaluate the safety and efficacy, and explore the dose range of Sym001 in Idiopathic Thrombocytopenic Purpura (ITP) patients. Sym001 is a recombinant, polyclonal anti-Rhesus D antibody product candidate. Symphogen and Biovitrum are jointly developing Sym001 under a...